Scholarlink

Background <p>Endometrial injury is a common cause of menstrual changes, abortion, and even infertility in women, including intrauterine adhesions (Asherman’s syndrome) and a thin endometrium. Hysteroscopic surgery and drug treatment are currently the main treatment methods; however, their effect is not satisfactory. Increasingly, studies have demonstrated that mesenchymal stem cells (MSCs) may be a safe and promising option for treating endometrial injury. This study aimed to evaluate the efficacy of MSCs in an endometrial injury model.</p> Methods <p>We searched PubMed, Cochrane Library, Web of Science, and EMBASE from the establishment of the databases to December 2023. Preclinical studies examining the role of MSCs in treating endometrial injury were included. The main outcome measures were the endometrial thickness, fibrosis area ratio, and recovery of reproductive function. Risk of bias assessment was performed using the SYRCLE tool. RevMan 5.3 was used for the meta-analysis and testing heterogeneity.</p> Results <p>A total of 10 Randomized Controlled Trials (RCTs) involving 230 animals were included. The analysis showed that after treatment with MSCs, the endometrium was significantly thickened (WMD 115.01&#xa0;μm, 95% CI (94.07–135.95&#xa0;μm)), the area ratio of endometrial fibrosis reduced (WMD − 29.88, 95% CI (− 36.61–−23.15)), and the pregnancy rate increased (RR 4.60, 95% CI (2.09–10.13)). Subgroup analyses indicated that Human amniotic mesenchymal stem cells (HA-MSCs) seemed to be more effective than other types. In addition, we found that the treatment’s efficacy is also affected by the route of administration, the type of transplantation, and other factors.</p> Conclusions <p>The results of this study indicate that treatment with MSCs (HA-MSCs delivered via intrauterine injection) exerts beneficial effects on endometrial injury in rats.Xenogeneic MSCs showed enhanced therapeutic potential relative to allogeneic MSCs in our experimental models.Taken together, these data highlight MSCs as a potentially valuable approach warranting additional research for the treatment of endometrial injury.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mesenchymal stem cell therapy for endometrial injury: a meta-analysis of preclinical studies

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月17日

查看全文
  • YangYang Liu,
  • Zahra Ghorbaninejad Koubanani,
  • DaZhou Jia,
  • Min Ma

摘要

Background

Endometrial injury is a common cause of menstrual changes, abortion, and even infertility in women, including intrauterine adhesions (Asherman’s syndrome) and a thin endometrium. Hysteroscopic surgery and drug treatment are currently the main treatment methods; however, their effect is not satisfactory. Increasingly, studies have demonstrated that mesenchymal stem cells (MSCs) may be a safe and promising option for treating endometrial injury. This study aimed to evaluate the efficacy of MSCs in an endometrial injury model.

Methods

We searched PubMed, Cochrane Library, Web of Science, and EMBASE from the establishment of the databases to December 2023. Preclinical studies examining the role of MSCs in treating endometrial injury were included. The main outcome measures were the endometrial thickness, fibrosis area ratio, and recovery of reproductive function. Risk of bias assessment was performed using the SYRCLE tool. RevMan 5.3 was used for the meta-analysis and testing heterogeneity.

Results

A total of 10 Randomized Controlled Trials (RCTs) involving 230 animals were included. The analysis showed that after treatment with MSCs, the endometrium was significantly thickened (WMD 115.01 μm, 95% CI (94.07–135.95 μm)), the area ratio of endometrial fibrosis reduced (WMD − 29.88, 95% CI (− 36.61–−23.15)), and the pregnancy rate increased (RR 4.60, 95% CI (2.09–10.13)). Subgroup analyses indicated that Human amniotic mesenchymal stem cells (HA-MSCs) seemed to be more effective than other types. In addition, we found that the treatment’s efficacy is also affected by the route of administration, the type of transplantation, and other factors.

Conclusions

The results of this study indicate that treatment with MSCs (HA-MSCs delivered via intrauterine injection) exerts beneficial effects on endometrial injury in rats.Xenogeneic MSCs showed enhanced therapeutic potential relative to allogeneic MSCs in our experimental models.Taken together, these data highlight MSCs as a potentially valuable approach warranting additional research for the treatment of endometrial injury.